Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008)
Active, not recruiting · NCT06049212 · Registry updated 2026-09-02Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Sacituzumab Tirumotecan (MK-2870) as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors (MK-2870-008) | Neoplasms by Site, Thoracic Neoplasms, autosomal dominant Parkinson disease 4, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 1 | 2026-09-02 | NCT06049212 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Merck Sharp & Dohme LLC | 650 |
7 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Aichi Cancer Center ( Site 0006) | Nagoya | Japan | 1 |
| Kanagawa Cancer Center ( Site 0004) | Yokohama | Japan | 1 |
| Kansai Medical University Hospital ( Site 0007) | Hirakata | Japan | 1 |
| National Cancer Center Hospital ( Site 0001) | Chuo-ku | Japan | 1 |
| National Cancer Center Hospital East ( Site 0002) | Kashiwa | Japan | 1 |
| National Hospital Organization Shikoku Cancer Center ( Site 0008) | Matsuyama | Japan | 2 |
| Shizuoka Cancer Center ( Site 0005) | Nagaizumi-cho,Sunto-gun | Japan | 1 |